Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

1. Eiermann, W.
2. Pienkowski, T.
3. Crown, J.
4. Sadeghi, S.
5. Martin, M.
6. Chan, A.
7. Saleh, M.
8. Sehdev, S.
9. Provencher, L.
10. Semiglazov, V.
11. Press, M.
12. Sauter, G.
13. Lindsay, M.-A.
14. Riva, A.
15. Buyse, M.
16. Drevot, P.
17. Taupin, H.
18. Mackey, J.R.